Skip to main content

Table 2 Metabolite identities and their relevant KEGG pathways in the top cluster of Figure 11

From: Exploring metabolic pathway disruption in the subchronic phencyclidine model of schizophrenia with the Generalized Singular Value Decomposition

Formula

Metabolite

Metaboite

KEGG ID

KEGG

Pathways

P-value

Ratio

C 5 H 10 N 2 O 3

L-Glutamine

c00064

Ko00230, ko00240, ko00250, ko00330

0.522

0.959

H 3 PO 4

Phosphoric acid

c00009

ko00190

0.254

0.915

C 5 H 7 NO 3

1-Pyrroline-4-hydroxy-2- carboxylate

c04282

ko00330

0.781

0.981

C 4 H 9 N 3 O 2

Creatine

c00300

ko00330, ko00260

0.551

0.953

C 4 H 9 NO 2

GABA

c00334

ko00250, ko00330, ko00410, ko04080, map00650

0.021

0.804

C 4 H 7 NO 4

L-Aspartate

c00049

ko00250, ko00260, ko00270, map00300, ko00330, ko00340, ko00410, ko00760, ko00770, ko04080

0.319

0.916

C 4 H 7 NO 2

1-Aminocyclopropane-1-carboxylate

c01234

ko00270, ko00640

0.590

0.951

C 5 H 5 N 5 O

Guanine

c00242

ko00230

0.035

0.593

C 5 H 9 NO 4

Glutamate

c00025

ko00250, ko00330, ko00340, ko00471, ko04080, ko00480, map00650

0.845

0.985

C 4 H 7 NO

Hydroxymethylpropanitrile

NA

NA

0.098

0.842

C6H6N2O

Nicotinamide

c00153

ko00760

0.440

0.917

C 4 H 6 O 2

2,3-Butanedione

c00741

map00650

0.017

0.786

C 6 H 12 O 4

Pantoate

c00552

ko00770

0.722

0.963

C 15 H 23 N 5 O 14 P 2

ADP-ribose

c00301

ko00230

0.058

677.029

C 3 H 7 NO 3

L-Serine

c00065

ko00260, ko00270, ko00600, ko00920, ko00680

0.316

0.856

C 4 H 5 N 3 O

Cytosine

c00380

ko00240

0.019

0.665

C 2 H 7 NO 3 S

Taurine

c00245

ko00430, ko04080

0.936

0.995

C 4 H 5 NO 3

Maleamate

c01596

ko00760

0.372

0.927

C 2 H 8 NO 4 P

Ethanolamine phosphate

c00346

ko00260, ko00564, ko00600

0.373

0.889

 

Unknown ID

NA

NA

0.271

1.395

C 5 H 11 NO 3

Hydroxyvaline

NA

NA

0.585

0.946

C 6 H 13 N 3 O 3

L-Citrulline

c00327

ko00330

0.007

0.709

  1. Table 2 shows the top cluster of metabolites identified by the GSVD algorithm that are present in the PFC of control but not PCP-treated animals (Figure 11). The molecular formula, tentative molecular identity, its KEGG compound identity and the KEGG metabolic pathways in which a given metabolite is involved are also shown. The key for each KEGG pathway identity is shown in Table 4. The p -values and ratio change reported for each metabolite in this table are those calculated by SIEVE analysis. Those metabolites found to be significantly different between the two groups by analysis are highlighted in bold. While SIEVE analysis fails to attribute significance (p < 0.05) to PCP-induced alterations in the overt concentration of many metabolites in this cluster, GSVD analysis reveals that the relationship between these metabolites is significantly altered by PCP treatment (p < 0.001), highlighting the specific metabolic pathways that may be disrupted in the PFC of PCP-treated animals. The most prominent alterations in KEGG defined pathways in this cluster were in (i) Arginine and Proline metabolism (7 metabolites [ko00330]) (ii) Glycine, Serine and Threonine metabolism (3 metabolites [ko00260]) and (iii) KEGG defined neuroactive ligands (4 metabolites [ko04080]).
Back to article page

BMC Systems Biology

ISSN: 1752-0509

Contact us